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Transthyretin cardiac amyloidosis (ATTR-CA) is a challenging and underdiagnosed cause of heart failure.
Advances in cardiac imaging have enabled noninvasive diagnosis of ATTR-CA, causing the recent upsurge
in disease awareness and detection. ATTR-CA has been increasingly recognized in patients with
degenerative aortic stenosis (AS). With the growing number of elderly patients undergoing aortic valve
intervention, the identification of ATTR-CA in this group of patients is of high clinical importance. Timely
and correct diagnosis is essential for amyloid-directed therapies, as well as deciding on the AS treatment
strategy. This review provides a comprehensive overview of the recent studies investigating coexistence
of these two entities. We present the data on the prevalence of ATTR-CA in AS and their prognostic
associations. As the diagnosis of ATTR-CA may be challenging, special attention is paid to the diagnostic
utility of different imaging modalities, namely, echocardiography, cardiovascular magnetic resonance,
nuclear imaging, and distinctive imaging features, in patients with dual pathology. We also present a
flowchart summarizing integrated imaging in patients with suspected ATTR-CA.
© 2019 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Transthyretin cardiac amyloidosis (ATTR-CA) is described as a
progressive infiltrative cardiomyopathy with ventricular wall
thickening and, predominantly, diastolic heart failure.1 ATTR-CA
can be either hereditary, resulting from >120 mutations in thethyretin cardiac amyloidosis;
trocardiography; ECV, extra-
cement; LV, left ventricular;
catheter aortic valve replace-
ono-1,2-propanodicarboxylic
hylene diphosphonate; Tc-
riskiu st. 2, 08661, Vilnius,
G. Balciunaite).
ty of Cardiology.
lishing services by Elsevier B.V. Thitransport protein transthyretin, or acquired, wild-type ATTR-CA.2,3
Until recently, ATTR-CA was considered a rare type of infiltrative
cardiomyopathy, and traditional gold standard for diagnosis was
positive endomyocardial biopsy in the context of characteristic
clinical and imaging features. Advances in diagnostic imaging,
including contrast-enhanced cardiovascular magnetic resonance
(CMR) with T1 mapping.4 and nuclear imaging with technetium-
labeled bone-seeking tracers,5,6 permit noninvasive, non-
histological diagnosis of ATTR-CA that substantially increased dis-
ease awareness and recognition in the last decade.7 Degenerative
aortic stenosis (AS) is the most common valvular heart disease in
developed countries.8 Excessive remodeling of the left ventricular
(LV) myocardium and restrictive physiology with preserved LV
ejection fraction are both features of ATTR-CA and AS.3,9 The
prevalence of both ATTR-CA and AS increases with age, and a
growing number of studies have investigated their coex-
istence.10e16 As both diseases share similar clinical ands is an open access article under the CC BY-NC-ND license (http://creativecommons.
G. Balciunaite et al. / Hellenic Journal of Cardiology 61 (2020) 92e98 93echocardiographic characteristics, recognition of superimposed
ATTR-CA in patients with AS can be very challenging. However,
accurate diagnosis is critical for the management of both pathol-
ogies, guiding amyloid-directed therapies and deciding on the AS
treatment strategy. In this review, we aimed to summarize the
available evidence on prevalence, diagnostic implications, and
prognostic associations of ATTR-CA in patients with AS.2. Prevalence of ATTR-CA in aortic stenosis
Data from postmortem studies in unselected subjects indicate a
prevalence of cardiac amyloidosis of 22% to 25% in subjects older
than 80 years of age.17 In an autopsy series of patients who had
undergone transcatheter aortic valve replacement (TAVR), varying
degrees of ventricular myocardium amyloid infiltration was found
in approximately one-third of cases.18 In a recent series, the pro-
portion of patients with AS identified with ATTR-CA varied greatly
and was between 4% and 16%.10,14,15,16 The large variability in the
prevalence of ATTR-CA in patients with AS could be explained by
different study inclusion criteria and diverse study populations
investigated (Table 1). The higher prevalence of ATTR-CAwas found
in TAVR cohorts. Scully et al16 reported 13.9% prevalence of ATTR-CA
in patients with severe AS referred for TAVR. In a study by Castano
et al,15 occult ATTR-CA was identified in 16% of patients after TAVR.
The lower prevalence of ATTR-CA was described in a cohort of pa-
tients with severe AS undergoing surgical AVR (SAVR). Amyloid
deposition was identified in endomyocardial biopsies of 6 out of
146 (4%) patients at the time of SAVR.10 The prevalence increased to
5.6% if only patients with calcific AS >65 years of age were
considered. On average, patients in that study were younger and
had preserved LV ejection fraction, representing a lower risk pop-
ulation and explaining lower prevalence of ATTR-CA. In a retro-
spective study by Cavalcante et al,14 among 113 patients with severe
and moderate AS, 9 had cardiac amyloidosis confirmed by CMR
with Late gadolinium enhancement (LGE). It appears that approx-
imately 1 in 7 patients currently undergoing TAVR have occult
cardiac amyloidosisda higher prevalence than that in surgical AVRTable 1
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diphosphono-1,2-propanodicarboxylic acid; EMB ¼ endomyocardial biopsy; HMDP¼T
PYP¼Tc-99m-pyrophosphate; SAVR ¼ surgical aortic valve replacement; TAVR ¼ transccohorts. Furthermore, ATTR-CA typically affects males more than
females, and the prevalence increases progressively with age. It has
important clinical implications, as with aging population, the
number of patients with coexistent ATTR-CA and severe AS will
likely increase.
3. Diagnosing ATTR-CA in aortic stenosis
Recognition of ATTR-CA is complex owing to variability in dis-
ease clinical presentation, absence of disease specific symptoms,
and ambiguous findings using common diagnostic tools. Diagnosis
of ATTR-CA in AS is evenmore difficult, as their clinical and imaging
features can overlap. Comorbidities such as coronary heart disease
and hypertension frequently present in the older population, which
creates a diverse clinical picture and adds to diagnostic challenges.
3.1. Electrocardiography
Patients with ATTR-CA rarely have normal electrocardiography
(ECG). The most commonly observed electrocardiographic abnor-
mality is a pseudoinfarct pattern (mainly in anterior leads),
observed in approximately 60% of patients with ATTR-CA.19e21 The
association between low voltage and cardiac amyloidosis has long
been considered pathognomonic; however, the prevalence in a
contemporary series of ATTR-CAwas as low as 20% to 30%.19,21,22 On
the contrary, up to a fifth (7-10%) of patients with ATTR-CA may
show LV hypertrophy on ECG.19,20 Direct involvement of the sino-
atrial node, atrioventricular node and bundle branches can mani-
fest as various degrees of conduction abnormalities.19,23 As
myocardial amyloid deposition is a continuum from minimal to
transmural, all the above-mentioned ECG abnormalities tend to
become more frequent with increasing disease severity. In a cohort
of 425 patients with ATTR-CA, presence of low ECG voltage, path-
ologic Q waves and duration of PR, QRS, and QT intervals progres-
sively increased with increasing thickness of interventricular
septum and were most common in patients with the thickest
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In a study by Castano et al,15 patients with AS diagnosed with ATTR-
CA compared to those with isolated AS had longer QRS duration
(127ms vs.110ms, p¼ 0.017) and higher prevalence of right bundle
branch block (37.5% vs. 15.8%, p ¼ 0.023). The most common
arrhythmia in a reported series was atrial fibrillation, present in
41.7-67% of patients with concomitant AS and ATTR-CA 11,12,14,15
(Table 2). Although atrial fibrillation is a frequent comorbidity of
the AS population, in patients with dual pathology, the prevalence
of atrial arrhythmias was significantly higher: 67% in the ATTR-CA
group vs. 20.2% in the isolated AS group, p ¼ 0.006.14 In sum-
mary, multiple ECG findings may suggest ATTR-CA but are
nonspecific in isolation. Pseudoinfarct pattern, low ECG voltage,
conduction abnormalities, and presence of atrial arrhythmias in a
context of other compatible clinical signs should alert physicians to
suspect cardiac amyloidosis.
3.2. Echocardiography
Echocardiography is the initial test in a pathway leading to the
diagnosis of ATTR-CA. However, classical echocardiographic fea-
tures such as left and right ventricular wall thickening, biatrial
dilatation, mild pericardial effusion, thickening of atrioventricular
valves and atrial septum, and restrictive filling pattern1 may be
absent at an early stage of the disease. Moreover, the absence of
increased ventricular wall thickness does not exclude the disorder,
as up to one-third of cases can present with normal LV wall size.24
Increased myocardial echogenicity, termed “granular sparking,”
strongly suggests cardiac amyloid, but it also becomes apparent at
the late phase of the disease. It was traditionally believed that a
concentric hypertrophic pattern is a classical feature of infiltrative
cardiomyopathies, including cardiac amyloidosis. However, the
data from the most recent echocardiographic and CMR studies19,25
show that an asymmetric pattern does not exclude amyloid depo-
sition, as asymmetrical septal hypertrophy was the most common
morphologic phenotype, found in 79% of patients with ATTR-CA.25
LV wall thickening, impaired diastolic filling, and/or LV systolic
dysfunction is frequently present in both pathologies. Nevertheless,
these alterations appear to be expressed to a higher degree in pa-
tients with coexisting ATTR-CA. Patients with coexisting ATTR-CA
and AS, in comparison to those with isolated AS, manifest greater
LV wall thickness and higher LV mass index e mean wall thickness
18mm ± 0.5 vs. 13mm ± 0.3, mean LVmass index 105 g/m2 ± 21 vs.
73 g/m2 ± 21.14 Diastolic dysfunction is another common finding inTable 2
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Castano, 201715 86.3 ± 5.7 91.7 41.7 0/25/75/0 13 ± 0.3 47.6 ± 17.6
Scully,
201816
88 ± 6 50 e e e e
Mean 83 75.6 55.8 17 51.5
Values are represented as mean ± SD or n (%). AF ¼ atrial fibrillation; AS ¼ aortic stenosi
thickness; LGE(þ) ¼ late gadolinium enhancement positive; LVEF ¼ left ventricular e
Association.both of these entities, which progresses from a delayed relaxation
pattern in the early stage through a pseudonormal pattern to a
restrictive filling pattern in the late stage of the disease.26,27 Pa-
tients with coexisting AS and ATTR-CA, compared to those with
solely AS, exhibitedmore advanced grade of diastolic dysfunctione
E/A ratio 2.3 vs. 0.9, p ¼ 0.001; E wave deceleration time 176 ms vs.
257 ms, p < 0.0001).15
Low-flow low-gradient AS physiology should raise a suspicion
for cardiac amyloid deposition, as it was frequently observed in
reported series. Four studies have demonstrated that patients with
AS and concomitant ATTR-CA, compared to those with isolated AS,
had significantly lower LV ejection fraction, lower stroke volume
index, and lower trans-aortic gradient.11,13,14,15 In a study by Cav-
alcante et al,14 out of 9 patients with AS diagnosed with ATTR-CA, 7
(78%) exhibited a low-flow low gradient pattern. Similarly, Galat
et al11 have found low-flow low-gradient AS physiology in 12 (86%)
out of 14 patients with ATTR-CA. The observation of a loweflow
low-gradient hemodynamic profile can serve as a red flag for car-
diac amyloidosis and prompt search for other echocardiographic or
clinical markers of the disease.
3.3. Deformation imaging
The analysis of myocardial deformation by tissue Doppler and
speckle-tracking echocardiography plays an important role in the
recognition of cardiac amyloidosis.28 Reduction in LV longitudinal
deformation is an early marker of cardiac amyloid deposition and
may be detected even before LV wall thickening of heart failure
occurs.29e31 In a recent series, patients with concomitant ATTR-CA
and AS exhibited significantly reduced LV longitudinal deformation
measured by tissue Doppler or 2D speckle tracking.10,11,15 In a study
by Castano et al15 patients with dual pathology compared to those
with isolated AS had more impaired LV longitudinal deformation e
global longitudinal strain 12% vs. 16%, respectively, p ¼ 0.007;
mitral annular tissue Doppler S0 4.0 cm/s vs. 6.6 cm/s, respectively,
p < 0.0001.15 Furthermore, average mitral annular S0 was the best
predictor of ATTR-CA in a multivariable logistic regression analysis,
and a cut-off value of S' < 6 cm/s conferred 100% sensitivity to
predict a positive 99mTc-PYP (99mTc-labeled pyrophosphate)
amyloid scan. However, the relative apical sparing, with lower
longitudinal deformation in basal segments with regard to apical
ones, was not depicted in patients with ATTR-CA in that study. It has
been speculated that the observed reduction in apical longitudinal
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s; AV ¼ aortic valve; GLS ¼ global longitudinal strain; IVST ¼ interventricular septal
jection fraction; LVSV ¼ left ventricular stroke volume; NYHA¼ New York Heart
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deposition of amyloid in comparison to other segments. Therefore,
the discriminatory value of 2D speckle-tracking in patients with
dual pathology requires further investigation, as a classical apical-
sparing pattern may be concealed by the presence of AS.
3.4. Cardiovascular magnetic resonance
CMR imaging has a high diagnostic value in cardiac amyloidosis
and provides additive information through myocardial tissue char-
acterization. LGE on CMR is very common in cardiac amyloidosis and
represents interstitial expansion from amyloid deposition. The most
frequent prototypical pattern is subendocardial and global trans-
mural LGE, which is associated with the greatest interstitial amyloid
deposition on myocardial histology.25,32,33 Regional differences in
LGE distribution have been described in patients with ATTR-CA, with
higher involvement of basal segments and decreasing involvement
extending to mid-cavity and apical levels.33e35 CMR also enables
more detailed evaluation of amyloid deposition in other parts of the
heart. Right ventricular LGE is also extremely common and found in
37% to 97% of patients with ATTR-CA, depending on the stage of the
disease.36 Increased left atrial wall thickness and left atrial wall LGE
were found in 70% and 90% of patients with ATTR, respectively.37
(Fig. 1). There may be absence of late enhancement in cardiac
amyloidosis, which should be taken into account, as amyloid depo-
sition is a continuum from no LGE to subendocardial to transmural.38
It appears that patients with biopsy-proven cardiac amyloidosis, but
negative orminor LGE, have less advanced stage of the disease,32 and
restricting CMR protocols to LGE imaging carries the risk of missing
early stages of cardiac amyloidosis.
Nonischemic patchy or mid-wall LGE is also found in approxi-
mately one-third of patients with severe AS and associated with
impaired cardiac function and adverse clinical outcomes.39 There-
fore, patients with dual pathology may present with various com-
binations of CMR-LGE, creating difficulties in ATTR identification.
3.5. T1 mapping
Amyloid infiltration results in expansion of the extracellular
space, which can be measured with T1 mapping, providing aFigure 1. Multimodality imaging of a patient with advanced ATTR cardiac amyloidosis. (A)
cordial leads. (B) Echocardiographic parasternal short-axis view showing increased left ventr
with global subendocardial circumferential enhancement of left ventricular walls in four-c
interatrial septum, both atria (arrows) and right ventricular wall. Endomyocardial biopsy wi
with anti-TTR antibodies.novel tool to detect and quantify amyloid load. Elevated native
myocardial T1 and extracellular volume (ECV) in cardiac ATTR
was shown to be more sensitive than LGE imaging and had high
diagnostic accuracy.4,7,25 ECV was found to be elevated in patients
with an early-stage disease when conventional clinical testing
and LGE were normal.4 Native T1 and ECV values become
abnormal sequentially with increasing cardiac amyloid burden,
being normal or mildly abnormal at an early stage and attaining
the highest values at the advanced stage of the disease.36,38 To
date, only one study investigated native T1 and ECV values in
patients with concomitant ATTR-CA and AS. The authors reported
that, compared to patients with isolated AS, patients with
concomitant ATTR-CA exhibited higher native T1 and ECV values:
mean ECV 41.2% ± 16.7 vs. 27.9% ± 4.1, p < 0.001; mean native T1
1125 ms ± 49 vs. 1035 ms ± 60, p ¼ 0.002.143.6. Nuclear imaging
Recent advances in nuclear imaging revolutionized ATTR-CA
detection methodology. A new diagnostic algorithm was pro-
posed and validated in 2016 that enabled noninvasive, non-
histological diagnosis of ATTR amyloid deposition, diminishing
the need for an endomyocardial biopsy. Three technetium-
labeled radiotracers have been evaluated clinically for ATTR-
CA identification: Tc-99m-pyrophosphate (PYP), Tc-99m-3,3-
diphosphono-1,2-propanodicarboxylic acid (DPD), and Tc-
99m_hydroxymethylene diphosphonate (HMDP). It has been
shown that grade 2 or 3 uptake on scintigraphy and the
absence of a monoclonal protein have specificity and a positive
predictive value of 100% for ATTR-CA.40 Radionuclide bone
scintigraphy has high sensitivity and may identify cardiac ATTR
amyloid deposits early in the course of the disease, sometimes
before the development of abnormalities on echocardiography
or CMR.41 Diagnosis of cardiac ATTR amyloidosis should be
followed by TTR genotyping in all patients to differentiate
between wild-type and mutant ATTR-CA. In the mutant ATTR-
CA, the pathogenic mutation results in destabilization and
misfolding of the transthyretin protein, whereas in the wild-
type ATTR-CA, the genetic sequence of transthyretin is
normal and the aging process is believed to be responsible forECG showing atrial fibrillation, with a low-voltage, and pseudoinfarct pattern in pre-
icular wall thickness and mild pericardial effusion. Cardiac magnetic resonance imaging
hamber (C) and short-axis views (arrowheads) (D). Note the diffuse enhancement of
th ATTR-related amyloid infiltration: (E) Congo red staining, (F) immunohistochemistry
G. Balciunaite et al. / Hellenic Journal of Cardiology 61 (2020) 92e9896protein instability and altered aggregation. Histological confir-
mation and typing of amyloid may still be required in patients
undergoing a positive radionuclide scan and with the presence
of a monoclonal protein.3.7. Diagnostic workup of ATTR-CA in as
Given the high prevalence of calcific AS in the general popu-
lation and the increasing frequency of TAVR in elderly patients, it
is prudent to screen those in whom there is a suspicion of
concomitant ATTR-CA. Echocardiography with deformation anal-
ysis may be the initial diagnostic steps, followed by contrast-
enhanced CMR with T1 mapping. While endomyocardial biopsy
with histological staining and tissue typing remain the gold
standard for the diagnosis of ATTR-CA, it may not be appropriate
in frail elderly patients. Nuclear imaging with technetium-labeled
bone-seeking tracers, coupled with serum and urine electropho-
resis for exclusion of monoclonal protein, may be a more suitable
approach in this population (Fig. 2). However, owing to disease
heterogeneity and the wide spectrum of clinical presentation, the
optimal diagnostic algorithm for cardiac amyloidosis screening in
patients with AS is still unclear and needs to be sorted out by
further investigation.Figure 2. Flowchart of integrated imaging for the diagnosis of ATTR cardiac amyloidosis i
CMR ¼ cardiovascular magnetic resonance; DPD ¼ Tc-99m-3,3-diphosphono-1,2-propano
diphosphonate; IFE ¼ immunofixation electrophoresis; LGE ¼ late gadolinium enhancemen4. Prognosis of patients with ATTR-CA and AS
The ATTR-CA is characterized by years of relative stability and
slow disease progression. The reported median survival from
diagnosis in untreated patients is approximately 3.6 years; how-
ever, a major determinant of outcomes is the extent of cardiac
involvement.42 In a recent meta-analysis of 23 studies, the pre-
dictors of death in patients with cardiac amyloidosis (AL and ATTR
e wild and mutant types) were investigated.43 Multivariate pre-
dictors of mortality were NYHA functional class, mean LV wall
thickness, LV ejection fraction, and echocardiographic parameters
of diastolic dysfunction (restrictive filling pattern, E/E' ratio, and E
wave deceleration time). Right ventricular involvement, manifest-
ing as increased right ventricular wall thickness and systolic
dysfunction, is another independent predictor of poor prognosis in
cardiac amyloidosis. It has been shown that right ventricular lon-
gitudinal systolic dysfunction, as assessed by depressed right ven-
tricular longitudinal strain, is a negative prognostic marker in
cardiac amyloidosis.44
To date, 3 longitudinal studies have investigated outcomes of
patients with concomitant ATTR-CA and AS10,13,14 (Table 1). In all of
these studies, presence of ATTR-CA was associated with worse
outcomes. In a study by Treibel et al,10 146 patients with severe ASn aortic stenosis. AS ¼ aortic stenosis; ATTR-CA ¼ Transthyretin cardiac amyloidosis;
dicarboxylic acid; EMB ¼ endomyocardial biopsy; HMDP¼Tc-99m-hydroxymethylene
t; LV ¼ left ventricular; PYP¼Tc-99m-pyrophosphate; RV ¼ right ventricular.
G. Balciunaite et al. / Hellenic Journal of Cardiology 61 (2020) 92e98 97who underwent surgical AVR were followed up for a median of
2.3 years. Three out of 6 (50%) patients with AS who had ATTR-CA
died, while 8 out of 106 (7.5%) deaths were observed in patients
with isolated severe AS. Of all variables assessed, the presence of
ATTR-CA had the highest hazard ratio for all-cause mortality
(HR ¼ 9.5, 95% CI 2.5-35.8, p ¼ 0.001). In a retrospective study by
Cavalcante et al,14 patients with coexisting ATTR-CA had a higher 1-
year all-cause mortality than patients with isolated AS (56% vs. 20%,
p < 0.0001). Furthermore, patients with combined disease had
higher all-cause mortality rate even after adjustment of possible
confounders, including AVR, LV ejection fraction, and functional
class. Sperry et al12 in a retrospective study compared outcomes of
ATTR-CA patients with and without AS. Study revealed no signifi-
cant difference in the 2-year mortality rate between the two
groups: 37% in the ATTR-CA with AS group and 33% in the isolated
ATTR-CA group (HR ¼ 1.22, 95% CI: 0.62-2.42, p ¼ 0.566). These
results suggest that the mortality in patients with combined dis-
ease may be driven by the presence of ATTR-CA, as patients with AS
died at the same rate as those without AS despite some having
undergone AVR. There is a need to further evaluate whether
amyloidosis affects mortality synergistically with severe AS or
whether it is the primary driver of poor outcomes in patients.
5. Management of patients with ATTR-CA and AS
Recognition of ATTR-CA is important before aortic valve inter-
vention for better risk stratification and management choices, as
unrecognized ATTR-CA in symptomatic patients with severe AS
may be a cause of periprocedural complications in patients un-
dergoing aortic valve intervention.45 There are reports of periop-
erative mortality in ATTR-CA patients due to fatal arrhythmias,
progressive heart failure, and myocardial infarction with mechan-
ical complications.46,47 On the other hand, TAVR, which is indicated
for older and higher risk patients, is not without a risk as well.
There are reports of LV rupture and complete atrioventricular block
leading to death during or after the TAVR procedure in patients
with cardiac amyloidosis.48,49 Early diagnosis of ATTR-CA is also
critical to gain the best efficacy of amyloid-directed therapies.
Contemporary treatment strategies that stabilize transthyretin
have recently reported to improve survival in patients with ATTR-
CA.50 Tafamidis treatment, compared to placebo, resulted in lower
all-cause mortality, a 32% relative risk reduction in cardiovascular
hospitalizations, and a lower rate of decline in the 6-minute walk
test. The drug is currently under review by the U.S. Food and Drug
Administration for ATTR-CA. The question regarding its use in pa-
tients with AS remains unanswered and will require dedicated
prospective trials. There are no recommendations on the manage-
ment of patients with concomitant AS and ATTR-CA, which makes
the treatment of the coexisting diseases challenging for clinicians.
Currently, management choices are left to the discretion of the
treating heart team and should be discussed with each patient
individually. The decision to operate should depend on the type of
amyloidosis, the severity of the cardiac involvement, and the
overall patient prognosis. Cardiac biomarkers can be used to risk
stratify ATTR-CA patients. Two staging systems have been pro-
posed. Thresholds of troponin T (0.05 ng/ml) and NT-proBNP (3.000
pg/ml) were used by The Mayo Clinic staging system.42 The
respective 4-year survival estimates were 57%, 42%, and 18% for
stage I (both values below cutoff), stage II (one above), and stage III
(both above), respectively. The staging system from the U.K. Na-
tional Amyloidosis Center is applicable for both wild-type and
mutant ATTR-CA and discriminates patients into three prognostic
categories depending on their NT-proBNP levels and estimated
glomerular filtration rate.51 The risk and benefit of aortic valve
intervention should be carefully reconsidered in patients at stage IIIcardiac amyloidosis. Keeping in mind the higher risk of peri-
procedural complications and reduced overall survival in patients
with ATTR-CA, a more conservative approach may be adapted in
this population. Medical management with repeated aortic valve
balloon valvuloplasties could be preferred over valve replacement
strategies. However, at present, there are no studies comparing
different treatment strategies in patients with coexisting ATTR-CA
and AS. Prospective multicenter studies in larger cohorts of pa-
tients with AS are needed before the conclusions could be drawn
regarding the best management strategy. There is also lack of data
whether aortic valve replacement will improve long-term survival
in these patients. Outcome data are pending, but early results
suggest higher medium-term mortality in patients referred for
TAVR with severe AS (ATTRact-AS Study, NCT03029026). Our pro-
spective multicenter study (NCT03585933) also aims at deter-
mining the prevalence, phenotype, and outcomes of ATTR-CA in
patients with severe AS undergoing surgical and transcatheter AVR.
6. Conclusion
ATTR cardiac amyloidosis appears to be prevalent in AS,
particularly among octogenarian males undergoing TAVR. Identifi-
cation of cardiac amyloid deposition in the context of AS may be
challenging because of overlapping clinical and imaging features.
However, the presence of ATTR-CA is associated with a more severe
AS phenotype, especially low-flow low-gradient AS. Preliminary
data show that coexistence of ATTR-CA and AS is associated with
worse outcomes, irrespective of the AS treatment received. Further
work is pending to determine the optimal screening algorithm, AS
management strategy, and to refine our understanding of the role
of ATTR cardiac amyloidosis in these patients.
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